The occurrence of multi-drug resistant highly pathogenic avian influenza virus (HPAIV) strains highlights the urgent need for strategies for the prevention and control of avian influenza virus. The aim of our current study is to evaluate the antiviral activity of dryocrassin ABBA isolated from Rhizoma Dryopteridis Crassirhizomatis (RDC) against an amantadine-resistant H5N1 (A/Chicken/Hebei/706/2005) strain in a mouse model. Post inoculation with HPAIV H5N1 virus in mice, the survival rate was 87, 80, and 60% respectively in the 33, 18, and 12.5 mg/kg dryocrassin ABBA-treated groups. On the other hand, the survival rate was 53 and 20%, respectively in the amantadine-treated group and untreated group. Mice administered with dryocrassin ABBA or amantadine showed a significant weight increase compared to the untreated group. Moreover, 33 and 18 mg/kg dryocrassin ABBA have decreased lung index (P >0.05) and virus loads (P <0.01) compared to the untreated group on day 7. Also, on day 7 bronchoalveolar lavage fluid pro-inflammatory cytokines (IL-6, TNF-α, and IFN-γ) decreased significantly (P <0.01) while anti-inflammatory cytokines (IL-10 and MCP-1) were increased significantly (P <0.01) in the 33 and 18 mg/kg dryocrassin ABBA-treated groups compared to the amantadine group and the untreated group. Moreover, the concentrations of IL-12 in drug-treated groups were significantly (P < 0.01) lowered compared with the untreated group. Based on the above we conclude that orally administered dryocrassin ABBA provided mice protection against avian influenza virus H5N1 by inhibiting inflammation and reducing virus loads. Dryocrassin ABBA is a potential novel lead compound which had antiviral effects on amantadine-resistant avian influenza virus H5N1 infection.

中文翻译：

---

Dryocrassin ABBA，一种抗金刚烷胺抗H5N1禽流感病毒的新型活性物质。

多药耐药性高致病性禽流感病毒（HPAIV）菌株的出现凸显了迫切需要预防和控制禽流感病毒的策略。我们当前研究的目的是评估分离自鼠疫根霉（RDC）的dryocrassin ABBA对小鼠模型中耐金刚烷胺的H5N1（A / Chicken / Hebei / 706/2005）菌株的抗病毒活性。在小鼠中接种HPAIV H5N1病毒后，在33、18和12.5 mg / kg干骨胶原ABBA治疗组中，存活率分别为87％，80％和60％。另一方面，金刚烷胺治疗组和未治疗组的生存率分别为53％和20％。与未治疗组相比，给予干骨胶原ABBA或金刚烷胺的小鼠体重显着增加。而且，与第7天的未治疗组相比，33和18 mg / kg的干球蛋白ABBA的肺指数（P> 0.05）和病毒载量（P <0.01）降低。而且，在第7天，支气管肺泡灌洗液促炎细胞因子（IL-6）在33和18 mg / kg的干骨蛋白ABBA-中，TNF，α和IFN-γ显着降低（P <0.01），而抗炎细胞因子（IL-10和MCP-1）显着增加（P <0.01）。与金刚烷胺组和未治疗组相比。此外，与未治疗组相比，药物治疗组中的IL-12浓度显着降低（P <0.01）。基于上述内容，我们得出结论，口服干骨胶原ABBA可通过抑制炎症和减少病毒载量，为小鼠提供抗禽流感病毒H5N1的保护。